Impact of postoperative chemotherapy in patients resected for esophagogastric adenocarcinoma with major pathological response after preoperative chemotherapy: a study from the FREGAT database.

Fiche publication

Date publication

juillet 2026

Journal

Therapeutic advances in medical oncology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr BOUCHE Olivier , Pr LEPAGE Côme , Dr PAQUETTE Brice , Pr BRIGAND Cécile

Tous les auteurs :
Corazzin L, Jeanbert E, Glehen O, Gronnier C, Sulpice L, Gornet JM, Paquette B, Regimbeau JM, Brigand C, D'Journo XB, Brichon PY, Gagnaire J, Voron T, Mathonnet M, Penna C, Regenet N, Lepage C, Carrere N, Marchese U, Benhaim L, Fabre JM, Di Fiore F, Borie F, Bonnot PE, Bouché O, Tougeron D, Adenis A, Piessen G, Muller M,

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/42466102

Résumé

In locally advanced esophagogastric adenocarcinoma (EGA), perioperative chemotherapy is the standard of care and can result in complete/major pathological response. In this setting, real-world data on the impact of postoperative chemotherapy are scarce.